ADCT News & Events

Reports Q1 revenue $20.0M, consensus $19.99M. As of March 31, cash and cash equivalents were $231.0M vs. $261.3M as of December 31, 2025. The company has an expected cash runway at least into 2028. "During Q1, we continued to build momentum across our ZYNLONTA program," said CEO . "Looking ahead, we have multiple near-term catalysts, including topline results from LOTIS-5 anticipated in Q2, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead. We believe that we are well-positioned to expand ZYNLONTA's role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027."

ADC Therapeutics files to sell 9.83M common shares for holders

Reports Q4 revenue $23.06M, consensus $22.29M. "Building off the meaningful progress achieved across our ZYNLONTA clinical program in DLBCL and through investigator-initiated trials in indolent lymphomas this past year, we believe we have laid the foundation for multiple anticipated value-creating catalysts," said Ameet Mallik, CEO of ADC Therapeutics. "We expect topline LOTIS-5 results in the second quarter, followed by full LOTIS-5 and LOTIS-7 results in 2L+ DLBCL by the end of 2026 and, assuming positive data, potential compendia inclusions in first half of 2027 with LOTIS-5 regulatory approval to follow. Supported by an expected cash runway at least into 2028, we are confident we will drive significant potential long-term growth beginning in 2027."